Vascular Medicine A2043 JACC April 1, 2014 Volume 63, Issue 12 IMPACT OF DRUG-ELUTING STENT PLACEMENT COMPARED WITH BARE METAL STENT IN FEMOROPOPLITEAL DISEASE Moderated Poster Contributions Hall C Monday, March 31, 2014, 10:00 a.m.-10:15 a.m. Session Title: Platelets, Stents and Genes in Peripheral Artery Disease Abstract Category: 31. Vascular Medicine: Endovascular Therapy Presentation Number: 1282M-369B Authors: Norihiko Kamioka, Yoshimitsu Soga, Yusuke Tomoi, Yohei Kobayashi, Kokura Memorial Hospital, Kitakyushu, Japan Background: The efficacy of drug-eluting stent (DES) implantation for the femoropopliteal (FP) disease in the real world is not yet clarified compared with bare metal nitinol stent (BMS). Methods: Between January 2004 and April 2013, 1150 consecutive patients who had received their first endovascular therapy for FP disease were identified. Of them, 377 cases (464 limbs) were analyzed in this study; 98limbs (21.1%) were implanted DES (Zilver PTX, Cook, Bloomington, IN), and 366 limbs (78.9%) were treated with BMS (S.M.A.R.T., Cordis J&J, Miami, FL). The primary outcome was defined as primary patency, and the secondary outcome as secondary patency, assisted-primary patency and major adverse limb events (MALE; included of any repeat revascularization or major amputation). Results: The mean reference vessel diameter was 5.1±1.0 mm and the mean lesion length was 152.4±93.4 mm. There was no significant difference in primary patency between DES group and BMS group (65.8% vs 72.5% at 1year, P=.25), nor was there a significant difference with secondary patency, assisted-primary patency, and MALE (P=.41, .07, and .32, respectively). The independent predictors of primary patency were female gender, diabetes, history of coronary artery disease, administration of thienopyridine, and absence of cilostazol. Conclusions: In our study, the impact of DES for FP stenting was not proved on primary patency, secondary patency, assisted-primary patency and MALE.

IMPACT OF DRUG-ELUTING STENT PLACEMENT COMPARED WITH BARE METAL STENT IN FEMOROPOPLITEAL DISEASE

Download PDF Report

Upload
yohei
View
212
Download
0

Embed Size (px)

Citation preview

Page 1: IMPACT OF DRUG-ELUTING STENT PLACEMENT COMPARED WITH BARE METAL STENT IN FEMOROPOPLITEAL DISEASE

Vascular Medicine

A2043JACC April 1, 2014

Volume 63, Issue 12

impAct oF drug-eluting stent plAcement compAred with bAre metAl stent in FemoropopliteAl diseAse

Moderated Poster ContributionsHall CMonday, March 31, 2014, 10:00 a.m.-10:15 a.m.

Session Title: Platelets, Stents and Genes in Peripheral Artery DiseaseAbstract Category: 31. Vascular Medicine: Endovascular TherapyPresentation Number: 1282M-369B

Authors: Norihiko Kamioka, Yoshimitsu Soga, Yusuke Tomoi, Yohei Kobayashi, Kokura Memorial Hospital, Kitakyushu, Japan

background: The efficacy of drug-eluting stent (DES) implantation for the femoropopliteal (FP) disease in the real world is not yet clarified compared with bare metal nitinol stent (BMS).

methods: Between January 2004 and April 2013, 1150 consecutive patients who had received their first endovascular therapy for FP disease were identified. Of them, 377 cases (464 limbs) were analyzed in this study; 98limbs (21.1%) were implanted DES (Zilver PTX, Cook, Bloomington, IN), and 366 limbs (78.9%) were treated with BMS (S.M.A.R.T., Cordis J&J, Miami, FL). The primary outcome was defined as primary patency, and the secondary outcome as secondary patency, assisted-primary patency and major adverse limb events (MALE; included of any repeat revascularization or major amputation).

results: The mean reference vessel diameter was 5.1±1.0 mm and the mean lesion length was 152.4±93.4 mm. There was no significant difference in primary patency between DES group and BMS group (65.8% vs 72.5% at 1year, P=.25), nor was there a significant difference with secondary patency, assisted-primary patency, and MALE (P=.41, .07, and .32, respectively). The independent predictors of primary patency were female gender, diabetes, history of coronary artery disease, administration of thienopyridine, and absence of cilostazol.

conclusions: In our study, the impact of DES for FP stenting was not proved on primary patency, secondary patency, assisted-primary patency and MALE.